Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$3.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,165
52-wk High
$5.32
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Lipocine Inc :U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged.Lipocine Inc - ‍FDA has assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​.  Full Article

Lipocine Inc Q3 loss per share $0.22
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Lipocine Inc :Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017.Q3 loss per share $0.22.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Lipocine Inc files for mixed shelf of up to $150 million
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Lipocine Inc :Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Clarus Therapeutics provides update on patent infringement lawsuit
Thursday, 13 Oct 2016 

Lipocine Inc : Clarus therapeutics provides update on patent infringement lawsuit against Lipocine’s oral product for testosterone replacement therapy . Clarus therapeutics - patent infringement lawsuit against Lipocine, Inc. that had been filed in U.S. District court in Delaware has been dismissed .Clarus Therapeutics - court found there was not immediate reason to hear case given Lipocine's failure to receive FDA market approval for LPCN-1021.  Full Article

Lipocine Q2 loss per share $0.32
Tuesday, 9 Aug 2016 

Lipocine Inc : Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S . Lipocine announces financial and operational results for the second quarter of 2016 .Q2 loss per share $0.32.  Full Article

Lipocine expects to incur about $370,000 of cash expenditures
Tuesday, 19 Jul 2016 

Lipocine Inc : Estimates it will incur approximately $370,000 of cash expenditures . Company began notifying affected employees on July 18, 2016 . Lipocine Inc says annual costs savings of $1.7 million are expected upon completion of restructuring plan . Approved a restructuring and reduction in force plan of eight employees, constituting approximately 33% of company's workforce . Expects to recognize most of these restructuring charges during three months ended September 30, 2016 .Annual costs savings of $1.7 million are expected upon completion of restructuring plan - SEC filing.  Full Article

Lipocine gets complete response letter for LPCN 1021 from FDA
Wednesday, 29 Jun 2016 

Lipocine Inc : Lipocine receives complete response letter (crl) for LPCN 1021 From U.S. Food And Drug Administration . Crl identified deficiencies related to dosing algorithm for label .Says received a CRL from United States Food And Drug Administration ("fda") regarding its NDA for LPCN 1021.  Full Article

Lipocine reports Q1 loss per share $0.38
Tuesday, 10 May 2016 

Lipocine Inc : Lipocine announces financial and operational results for the first quarter of 2016 .Q1 loss per share $0.38.  Full Article

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged